|
S.No |
Acronym |
Full Form |
|
1 |
AADA |
Abbreviated Antibiotic Drug Application |
|
2 |
AAO |
American Academy of Ophthalmology |
|
3 |
ADE |
Adverse Drug Event |
|
4 |
ADME |
Absorption, Distribution, Metabolism, and Excretion |
|
5 |
ADI |
Acceptable Daily Intake |
|
6 |
ADR |
Adverse Drug Reaction |
|
7 |
ADRS |
Adverse Drug Reporting System |
|
8 |
AGDUFA |
Animal Generic Drug User Fee Act |
|
9 |
AHU |
Air Handling Unit |
|
10 |
ALCOA |
Acronym referring to Attributable, Legible, Contemporaneous, Original and
Accurate. |
|
11 |
ALCOA PLUS |
Acronym referring to Attributable, Legible, Contemporaneous, Original and
Accurate ‘plus’ Complete, Consistent, Enduring, and Available. |
|
12 |
AME |
Absorption, Metabolism, Excretion |
|
13 |
ANDA |
Abbreviated New Drug Application |
|
14 |
ANOVA |
Analysis of Variance |
|
15 |
ANVISA |
Agência Nacional de Vigilância Sanitária |
|
16 |
AP |
Applicants Part (of EDMF) |
|
17 |
API |
Active Pharmaceutical Ingredient |
|
18 |
APIC |
Active Pharmaceutical Ingredients Committee |
|
19 |
APR |
Annual product review (APQR – Annual product quality review) |
|
20 |
AQL |
Acceptable Quality Level |
|
21 |
AR |
Analytical Reagent |
|
22 |
ARB |
Angiotensin Receptor Blocker |
|
23 |
ASHRAE |
American Society of heating, Refrgeration and |
|
24 |
ACE |
Air Conditioning Engineers |
|
25 |
ASM |
Active Substance Manufacturer |
|
26 |
ASME |
American Society of Mechanical Engineers |
|
27 |
ASMF |
Active Substance Master File |
|
28 |
ASQ |
American Society for Quality |
|
29 |
AST |
Accelerated Stability Testing |
|
30 |
ASTM |
American Society for Testing and Materials |
|
31 |
BA/BE |
Bioavailability / Bioequivalence |
|
32 |
BCS |
Biopharmaceutical Classification System |
|
33 |
BET |
Bacterial Endotoxin Test |
|
34 |
BFS |
Blow Fill Seal |
|
35 |
BI |
Biological Indicator |
|
36 |
BIND |
Biological Investigational New Drug |
|
37 |
BLA |
Biologics License Application (CBER) |
|
38 |
BMI |
Body Mass Index |
|
39 |
BMR |
Batch Manufacturing / Processing Record |
|
40 |
BOD |
Biological Oxygen Demand |
|
41 |
BOM |
Bill of Materials |
|
42 |
BOPP |
Biaxially Oriented Polypropylene |
|
43 |
BP |
British Pharmacopoeia |
|
44 |
BPC |
Bulk Pharmaceutical Chemical |
|
45 |
BPR |
Batch Packaging Record |
|
46 |
BRMS |
Biologics Regulatory Management System |
|
47 |
BSA |
Body Surface Area |
|
48 |
BSE |
Bovine Spongiform Encephalopathy (Mad Cow Disease) |
|
49 |
BSI |
British Standards Institute |
|
50 |
BST |
Bovine Somatotropin |
|
51 |
BsUFA |
Biosimilar User Fee Act |
|
52 |
BTD |
Breakthrough Therapy Designation |
|
53 |
BVC |
British Veterinary Codex |
|
54 |
CA |
Chemical Abstracts |
|
55 |
CAPA |
Corrective and preventive action |
|
56 |
CANDA |
Computer Assisted New Drug Application |
|
57 |
CAPLA |
Computer Assisted Product License Application |
|
58 |
CAS |
Chemical Abstracts Service |
|
59 |
CBE |
Changes Being Effected |
|
60 |
CBER |
Center for Biologics Evaluation and Research (FDA) |
|
61 |
CCIT |
Container Closure Integrity Test |
|
62 |
CDER |
Center for Drug Evaluation and Research (FDA) |
|
63 |
CDRH |
Center for Devices and Radiological Health (FDA) |
|
64 |
CDSCO |
Central Drug Standard Control Organization (India) |
|
65 |
CEP |
Certification of Suitability of European Pharmacopoeia Monographs |
|
66 |
CFR |
Code of Federal Regulations |
|
67 |
CFU |
Colony Forming Unit |
|
68 |
CJD |
Creutzfeldt Jakob Disease |
|
69 |
cGMP |
Current Good Manufacturing Practices |
|
70 |
CIP |
Clean in Place |
|
71 |
CMC |
Chemistry, Manufacturing and Controls |
|
72 |
CMO |
Contract Manufacturing Organization |
|
73 |
CMS |
Continuous Monitoring System |
|
74 |
CNS |
Central Nervous System |
|
75 |
COA |
Certificate of Analysis |
|
76 |
COI |
Conflict of Interest |
|
77 |
COMSTAT |
Compliance Status Information System |
|
78 |
COP |
Clean out of Place |
|
79 |
COPP |
Certificate of Pharmaceutical Products |
|
80 |
CoS |
Certificate of Suitability |
|
81 |
CPI |
Consumer Price Index |
|
82 |
CPP |
Critical Process Parameter |
|
83 |
CQA |
Critical Quality Attribute |
|
84 |
CR |
Complete Response (Letter) |
|
85 |
CRO |
Contract Research Organization |
|
86 |
CRS |
Contamination Response System |
|
87 |
CSA |
Controlled Substances Act |
|
88 |
CSV |
Computer System Validation |
|
89 |
CT |
Clinical Trial |
|
90 |
CTD |
Common Technical Document |
|
91 |
CVMP |
Committee on Veterinary Medical Products (EMA) |
|
92 |
DI |
Deionized Water |
|
93 |
DIN |
Drug Identification Number (Canada) |
|
94 |
DMF |
Drug Master File |
|
95 |
DOA |
Drugs of Abuse |
|
96 |
DOE |
Design of Experiment |
|
97 |
DOP |
Dioctyl Phthalate |
|
98 |
DQ |
Design Qualification |
|
99 |
DP |
Drug Product |
|
100 |
DPC PTR Act |
Drug Price Competition and Patent Trade Restoration Act of 1984 |
|
101 |
DPI |
Dry Powder Inhaler |
|
102 |
DS |
Drug Substance |
|
103 |
DUNS |
Data Universal Numbering System |
|
104 |
EC |
European Community |
|
105 |
ED |
Effective Dose |
|
106 |
EDMF |
European Drug Master File |
|
107 |
EDQM |
European Directorate for the Quality of Medicines |
|
108 |
EFOIA |
Electronic Freedom of Information Act |
|
109 |
EFPIA |
European Federation of Pharmaceutical Industries and Associations |
|
110 |
EFTA |
European Free Trade Association |
|
111 |
EH&S |
Environmental Health and Safety |
|
112 |
EIA |
Enzyme Immunoassay |
|
113 |
EIR |
Establishment Inspection Report (FDA) |
|
114 |
EMA |
European Medicines Agency |
|
115 |
EP |
European Pharmacopoeia |
|
116 |
EPAR |
European Public Assessment Reports (EMEA) |
|
117 |
EPS |
Expanded Polystyrene |
|
118 |
ERP |
Emergency Response Plan |
|
119 |
ERS |
Electronic Regulatory Submission |
|
120 |
ERSR |
Electronic Regulatory Submissions and Review |
|
121 |
ESG |
Electronic Submissions Gateway |
|
122 |
ETP |
Effluent Treatment Plant |
|
123 |
EU |
Endotoxin Unit |
|
124 |
EU |
European Union (EU 27) |
|
125 |
FAI |
Further Action Indicated (FDA) |
|
126 |
FAR |
Field Alert Report (FDA) |
|
127 |
FAT |
Factory Acceptance Testing |
|
128 |
FBD |
Fluid Bed Dryer |
|
129 |
FDA |
Food and Drug Administration, United States |
|
130 |
FDA Form 482 |
FDA form for Notice of Inspection |
|
131 |
FDA 483 |
FDA form Used as a Written Notice of Deficiencies Found in Inspections |
|
132 |
FDA SRS |
Spontaneous Reporting System of the Food and Drug Administration |
|
133 |
FDC |
Food, Drug, & Cosmetic |
|
134 |
FDC |
Fixed Dose Combination |
|
135 |
FDCA |
Federal Food, Drug, and Cosmetic Act of 1938 |
|
136 |
FFDCA |
Federal Food, Drug, and Cosmetic Act of 1938 |
|
137 |
FEI |
Facility Establishment Identifier |
|
138 |
FEFO |
First Expiry First Out |
|
139 |
FG |
Finished Goods |
|
140 |
FIFO |
First in First Out |
|
141 |
FMEA |
Failure Modes and Effect Analysis |
|
142 |
FMECA |
Failure Modes Effects and Criticality Analysis |
|
143 |
FOI |
Freedom of Information |
|
144 |
FOIA |
Freedom of Information Act |
|
145 |
FR |
Federal Register |
|
146 |
FTA |
Fault Tree Analysis |
|
147 |
GAMP |
Good Automated Manufacturing Practice |
|
148 |
GARR |
Grants Application Review Request |
|
149 |
GC |
Gas Chromatography |
|
150 |
GCLP |
Good Clinical Laboratory Practice |
|
151 |
GCP |
Good Clinical practice |
|
152 |
GDP |
Good Distribution practice |
|
153 |
GEO |
Genetically Engineered Organism |
|
154 |
GEP |
Good Engineering Practice |
|
155 |
GGP |
Good Guidance practice |
|
156 |
GIT |
Gastrointestinal Tract |
|
157 |
GLP |
Good Laboratory Practice |
|
158 |
GMO |
Genetically Modified Organism |
|
159 |
GMP |
Good Manufacturing Practice |
|
160 |
GPT |
Growth Promotion Test |
|
161 |
GRAS |
Generally Recognized as Safe |
|
162 |
GRAS/E |
Generally Recognized as Safe and Effective |
|
163 |
GRP |
Good Review Practice |
|
164 |
GUDUFA |
Generic Drug User Fee Amendments |
|
165 |
GxP |
"Good x"" Practices |
|
166 |
HACCP |
Hazard Analysis Critical Control Point |
|
167 |
HCI |
Human Computer Interaction |
|
168 |
HDPE |
High Density Polyethylene |
|
169 |
HEPA |
High Efficiency Particulate Air (filter) |
|
170 |
HMI |
Human Machine Interface |
|
171 |
HPLC |
High Performance Liquid Chromatography |
|
172 |
HSA |
Health Sciences Authority, Singapore |
|
173 |
HVAC |
Heating, Ventilating, and Air Conditioning |
|
174 |
ICAH |
International Council on Harmonisation |
|
175 |
IH |
In House |
|
176 |
IM |
Intramuscular |
|
177 |
IND |
Investigational New Drug |
|
178 |
INDA |
Investigational New Drug Application |
|
179 |
INN |
International Nonproprietary Name |
|
180 |
IP |
Indian Pharmacopeia |
|
181 |
IPA |
Isopropyl Alcohol |
|
182 |
IPC |
In process Control |
|
183 |
IPCS |
International Programme on Chemical Safety (WHO) |
|
184 |
IPEC |
International Pharmaceutical Excipients Council |
|
185 |
IQ |
Installation Qualification |
|
186 |
IR |
Immediate Release |
|
187 |
IR |
Information Request (Letter) |
|
188 |
ISO |
International Organization for Standardization |
|
189 |
ISPE |
International Society for Pharmaceutical Engineering |
|
190 |
IUPAC |
International Union of Pure and Applied Chemistry |
|
191 |
IV |
Intravenous |
|
192 |
JP |
Japanese Pharmacopoeia |
|
193 |
KOS |
Knowledge Organization System |
|
194 |
LAF |
Laminar air flow |
|
195 |
LAL |
Limulus Amoebocyte Lysate |
|
196 |
LAN |
Local Area Network |
|
197 |
LD |
Lethal Dose |
|
198 |
LD50 |
Lethal Dose where 50% of the Animal Population Die |
|
199 |
LDPE |
Low Density Polyethylene |
|
200 |
LIMS |
Laboratory Information Management System |
|
201 |
LIR |
Laboratory Investigation Report |
|
202 |
LOA |
Letter of Agreement |
|
203 |
LOA |
Letter of Authorization |
|
204 |
LOD |
Loss on Drying |
|
205 |
LOD |
Limit of Detection |
|
206 |
LOQ |
Limit of Quantification |
|
207 |
LR |
Laboratory Reagent |
|
208 |
LVPs |
Large Volume Parenterals |
|
209 |
MA |
Marketing Authorisation |
|
210 |
MAA |
Marketing Authorisation Application |
|
211 |
mAb |
Monoclonal Antibody |
|
212 |
MAC |
Maximum Allowable Carryover |
|
213 |
MAH |
Marketing Authorisation Holder (EC) |
|
214 |
MDA |
Medical Devices Agency (UK) |
|
215 |
MDD |
Maximum Daily Dose |
|
216 |
MDI |
Metered Dose Inhaler |
|
217 |
MDR |
Medical Device Reporting |
|
218 |
MDUFMA |
Medical Device User Fee and Modernization Act of 2002 |
|
219 |
MDUFSA |
Medical Device User Fee Stabilization Act of 2005 |
|
220 |
MFR |
Master Formula Record |
|
221 |
MEDSAFE |
Medicines and Medicinal Devices Safety Authority (New Zealand) |
|
222 |
MHRA |
Medicines and Healthcare Products Regulatory Agency (UK) |
|
223 |
MLD |
Minimum Lethal Dose |
|
224 |
MOA |
Method Of Analysis |
|
225 |
MRA |
Mutual Recognition Agreement |
|
226 |
MS |
Mass Spectroscopy |
|
227 |
MSDS |
Material Safety Data Sheets |
|
228 |
MTD |
Maximum Tolerated Dose |
|
229 |
NCE |
New Chemical Entity |
|
230 |
NAI |
No Action Indicated(FDA) |
|
231 |
NCR |
Non Conformance Report |
|
232 |
NDA |
New Drug Application |
|
233 |
NDC |
National Drug Code (FDA) |
|
234 |
NF |
National Formulary |
|
235 |
NIR |
Near Infra Red Spectroscopy |
|
236 |
NME |
New Molecular Entity |
|
237 |
NMR |
Nuclear Magnetic Resonance Spectroscopy |
|
238 |
NMT |
Not More Than |
|
239 |
NOAEL |
No Observable Adverse Effect Level |
|
240 |
NOC |
Notice of Compliance (Canada) |
|
241 |
NOD |
Notice of Deficiency (Canada |
|
242 |
NON |
Notice of Non compliance (Canada) |
|
243 |
NSAID |
Non Steroidal Anti Inflammatory Drug |
|
244 |
OAI |
Official Action Indicated(FDA) |
|
245 |
ODI |
Orally Disintegrating Tablet |
|
246 |
OEL |
Occupational Exposure Level |
|
247 |
OQ |
Operation Qualification |
|
248 |
OSD |
Oral Solid Dosage |
|
249 |
OSHA |
Occupational Safety And Health Administration |
|
250 |
OOS |
Out of Specification |
|
251 |
OOT |
Out of Trend |
|
252 |
OTC |
Over the counter |
|
253 |
PAC |
Post approval changes |
|
254 |
PACT |
Post Approval Commitment Tracking |
|
255 |
PAI |
Pre Approval Inspection(FDA) |
|
256 |
PAO |
Poly alpha olefin |
|
257 |
PAS |
Prior Approval Supplement(FDA) |
|
258 |
PAT |
Process Analytical technology |
|
259 |
PD |
Pharmacodynamics |
|
260 |
PDA |
Parenteral Drug Association |
|
261 |
PDE |
Permitted Daily Exposure |
|
262 |
PDUFA |
Prescription Drug User Fee Act |
|
263 |
PEPFAR |
Presidential Emergency Plan for AIDS Relief |
|
264 |
PET |
Preservative Efficacy Test |
|
265 |
PET |
Polyethylene |
|
266 |
Ph.Eur. |
Pharmacopeia Europa |
|
267 |
PIC/S |
Pharmaceutical Inspection Co operation Scheme |
|
268 |
PK |
Pharmacokinetics |
|
269 |
PLA |
Product License Application (CBER) |
|
270 |
PLAIR |
Pre Launch Activities Importation Request (USFDA) |
|
271 |
PLC |
Programmable Logic Control |
|
272 |
PMA |
Premarket Approval |
|
273 |
PMF |
Public Master File |
|
274 |
PMS |
Postmarketing Surveillance |
|
275 |
POM |
Prescription only medicine (UK) |
|
276 |
ppb |
Parts per Billion |
|
277 |
PPE |
Personal protective equipment |
|
278 |
Ppm |
Parts per Million |
|
279 |
PPM |
Planned Preventive Maintenance |
|
280 |
PQ |
Performance Qualification |
|
281 |
PQG |
Pharmaceutical Quality Group |
|
282 |
PUDUFA |
Prescription Drug User Fee Act (FDA) |
|
283 |
PV |
Process Validation |
|
284 |
PVC |
Polyvinyl Chloride |
|
285 |
PVDC |
Polyvinylidene Chloride |
|
286 |
PW |
Purified Water |
|
287 |
QA |
Quality Assurance |
|
288 |
QC |
Quality Control |
|
289 |
QbD |
Quality by design |
|
290 |
QbR |
Question based Review |
|
291 |
QD |
Once Daily |
|
292 |
QID |
Four Times a Day |
|
293 |
QM |
Quality Manual |
|
294 |
QMS |
Quality Management System |
|
295 |
QOD |
Every Other Day |
|
296 |
QP |
Qualified Person (EU) |
|
297 |
QRM |
Quality Risk Management |
|
298 |
QSD |
Quality System Dossier |
|
299 |
QSM |
Quality System Management |
|
300 |
QU |
Quality Unit |
|
301 |
RCR |
Risk Control Review |
|
302 |
R&D |
Research and Development |
|
303 |
REMS |
Risk Evaluation and Mitigation Strategy |
|
304 |
RH |
Relative Humidity |
|
305 |
RLAF |
Reverse Laminar Air Flow |
|
306 |
RLD |
Reference listed drug |
|
307 |
RM |
Raw Material |
|
308 |
RMS |
Reference Member State (Europe) |
|
309 |
RO |
Reverse Osmosis |
|
310 |
ROPP |
Roll On Pilfer Proof |
|
311 |
RS |
Related Substance |
|
312 |
RTR |
Refuse to Receive |
|
313 |
Rx |
Prescription |
|
314 |
SAL |
Sterility Assurance Level |
|
315 |
SAT |
Site Acceptance Test |
|
316 |
SDN |
Screening Deficiency Notice (Canada) |
|
317 |
SHPRA |
South African Health Products Authority [formally known as Medicines Control
Council (MCC) |
|
318 |
SIP |
Sterilization in lace/Steam in place |
|
319 |
SLS |
Sodium Lauryl Sulphate |
|
320 |
SME |
Subject Matter Expert |
|
321 |
SMF |
Site Master File |
|
322 |
SOP |
Standard Operating Procedure |
|
323 |
SPE |
Society for Pharmaceutical Engineering |
|
324 |
STD |
Sexually Transmitted Disease |
|
325 |
SUPAC |
Scale up and Post Approval Changes |
|
326 |
SVP |
Small Volume Parenteral |
|
327 |
TC |
Thermocouple |
|
328 |
TDI |
Tolerable Daily Intake |
|
329 |
TDS |
Total Dissolved Solids |
|
330 |
TGA |
Therapeutics Goods Administration (Australia) |
|
331 |
TLC |
Thin Layer Chromatography |
|
332 |
TID |
Three Times a Day |
|
333 |
TOC |
Total Organic Carbon |
|
334 |
TSE |
Transmissible Spongiform Encephalopathy |
|
335 |
UDI |
Unique Device Identification |
|
336 |
UNII |
Unique Ingredient Identifier |
|
337 |
USFDA |
United States Foods and Drugs Administration |
|
338 |
USP |
United States Pharmacopeia |
|
339 |
USPC |
U.S. Pharmacopeial Convention |
|
340 |
USP NF |
United States Pharmacopeia National Formulary |
|
341 |
URS |
User Requirement Specification |
|
342 |
UTI |
Urinary tract infection |
|
343 |
VAI |
Voluntary Action Indicated |
|
344 |
VMP |
Validation Master Plan |
|
345 |
WFI |
Water for Injection |
|
346 |
WHO |
World Health Organisation |
|
347 |
WL |
Warning letter |